Navigation Links
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Date:11/15/2012

RARITAN, N.J., Nov. 15, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort. 

(Logo: http://photos.prnewswire.com/prnh/20120117/LA36598LOGO)

The new Investigator Databank, established as part of this novel industry collaboration, will serve as a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed. This will allow participating pharmaceutical companies to reduce time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites.   

At the outset of every clinical trial, pharmaceutical companies initiate clinical trial site selection, prequalification and GCP training, which can be paperwork-heavy and time-consuming for trial sponsors and investigators alike. By housing critical information about investigators and trial sites in one place, the databank will reduce time, cost and duplicative efforts, making it easier for companies to identify appropriate trial sites and investigators for future clinical trials. Investigator sites that have opted-in to data sharing will have their relevant information accessible to pharmaceutical companies participating in the collaboration. This databank will not include any patient data.   

"The current clinical trial environment is inefficient, costly and unsustainable. The Investigator Databank can help expedite the process to achieve our most important goal – to deliver high-quality, effective novel medicines to the patients who are waiting for
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... The Bio-Process Systems Alliance (BPSA) is pleased ... (ISUS 2015) will be held July 13-15, 2015, ... primary focus on the promises and hurdles impacting the ... to business and regulatory presentations, ISUS 2015 will examine ... single-use industry as the "go-to" platform in bioprocessing. The ...
(Date:5/27/2015)... Manitoba , May 27, 2015 ... customers, the Canadian International Pharmacy Association (CIPA) ... medications online from licensed Canadian pharmacies. Approximately 64% of ... maintenance medications from a non-U.S. pharmacy due to ... are not covered under their insurance plan.   ...
(Date:5/27/2015)... ANGELES , May 27, 2015  CytRx Corporation ... company specializing in oncology, today announced an upcoming poster ... 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, ... 2015 in Chicago . ... profile we,re seeing in patients who have undergone treatment ...
Breaking Medicine Technology:BPSA's 5th Annual Summit to Provide '2020 Vision' for Single-Use Technologies 2BPSA's 5th Annual Summit to Provide '2020 Vision' for Single-Use Technologies 3Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 2Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 3CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 2CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 3CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 4CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 5
... WIRE)--Jun 27, 2007 - Annals of,Internal Medicine has ... the impact of genistein on bone loss. The ... in Osteopenic,Postmenopausal Women-A Randomized Trial," appears in the ... and efficacy of,genistein for the dietary management of ...
... - Opexa,Therapeutics, Inc. (NASDAQ:OPXA), a company involved ... presented,poster presentations at the 5th International Society ... Cairns, Queensland, Australia,from June 17-20 and at ... for Cellular Therapy (ISCT) in Sydney, Australia ...
Cached Medicine Technology:New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine 2New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine 3Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 2Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 3
(Date:5/27/2015)... TX (PRWEB) May 27, 2015 Congratulations ... The Torch” Addiction Treatment Scholarship Award. From June 1, ... $10,000 to 50 drug and alcohol addiction treatment centers ... treatment. Scholarships were drawn at random at addiction treatment ... for Sky Toxicology, Matt Green said, “Sky Toxicology would ...
(Date:5/27/2015)... Danish scientists have published an analysis of ... potential to help in diagnosis or treatment planning for ... that has just been posted on Surviving Mesothelioma. ... new biomarkers found in blood, serum, and lung fluid ... malignant mesothelioma . , Study author Vasiliki Panou ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 With the ... Studios, editors can quickly and easily add filmic color grades ... CUBE LUT files. , FCPX LUT Cross Processed Plugin can ... to contemporary looks and everything in between. , FCPX LUT ... be used in many different softwares. With the FCPX LUT ...
(Date:5/27/2015)... May 27, 2015 Widely regarded ... center for young adults ages 18 to 40, ... accreditation by The Joint Commission. The announcement ... Scottsdale, AZ regions, entailing a number of added ... detox and residential treatment program in lieu of ...
(Date:5/27/2015)... Lutz, Florida (PRWEB) May 27, 2015 ... with its digital partner, award winning web ... is proud to announce the launch of ... http://www.nationalhealthcareproviders.com. , National Healthcare Providers, ... consulting firm, specializing in the areas of ...
Breaking Medicine News(10 mins):Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 2Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 3Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release FCPX LUT Cross Processed Plugin for Final Cut Pro X 2Health News:Arizona Drug Treatment Center SRC Announces JCAHO Accreditation 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3
... Scientists involved in a worldwide research have come up with ... ,This gel is expected to evolve into a powerful new ... it would be 95% efficient. ,Brazilian scientists, ... by using microbicides , assure the gel will be on ...
... Novacea , a drug company has designed a vitamin D ... D from sunlight is known to slow down certain cancers. ... effect. The drug, Asentar (DN-101) provides levels of vitamin D ... patients in the advanced stages of prostate cancer along with ...
... role of partners or couples in health care, according to ... of Archives of Dermatology, researchers came to the conclusion that ... to take the sessions more seriously and do the examination ... the dreaded melanoma or skin cancer. , Persons ...
... may exist a link between Vitamin A and gullet cancer. ... Research Council Cell Unit and her team. // ,Gullet ... the oesophageal lining. This condition is also called as Barrett’s ... is slowly changed to glandular lining. The reason for this ...
... South Asians have been known to get first-time heart attacks ... but this had been put down loosely to genes.,Not any ... researchers has come out with findings published in Journal of ... Asians (people originating from India, Pakistan, Srilanka, Nepal and. ...
... and health care clinics in China have been asked ... prepared to handle cases. //The Ministry of Health has ... rise in diarrhea cases. ,As Norovirus infections ... while eating in restaurants and hotels. These viruses are ...
Cached Medicine News:Health News:Vitamin D Tablets to Cure Prostate Cancer 2Health News:Pair Up-Prevent Melanoma 2Health News:South Asians, Don’t Blame Your Genes Anymor 2
... First Stop absorbable collagen hemostat. FirstStop is ... handling and removal characteristics. It can easily ... fit the wound. FirstStop products are not ... peeled away after hemostasis is achieved. As ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: